Brought to you by 
Advent International enters agreements to buy Zentiva from Sanofi for €1.9bn; deal closes
Apr 2018
Executive Summary
Sanofi confirmed that is in exclusive negotiations to divest its European generics business Zentiva BV to private equity firm Advent International for €1.9bn ($2.3bn). The deal is said to be binding and fully financed, and could close by the end of year, pending definitive agreements and regulatory approval.
Deal Industry
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Acquisition
- Payment Includes Cash
- Buy-out
- Divestiture/Spin-Out
- Full Acquisition
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Advent International enters agreements to buy Zentiva from Sanofi for €1.9bn; deal closes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice